Arvinas (ARVN)
(Delayed Data from NSDQ)
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Arvinas, Inc. (ARVN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$61.38 | $90.00 | $40.00 | 134.63% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Arvinas, Inc. comes to $61.38. The forecasts range from a low of $40.00 to a high of $90.00. The average price target represents an increase of 134.63% from the last closing price of $26.16.
Analyst Price Targets (16)
Broker Rating
Arvinas, Inc. currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 16 are Strong Buy, representing 88.89% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ARVN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 16 | 16 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/1/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
7/31/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
7/31/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
7/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/26/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
5/8/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/28/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
2/14/2024 | Not Identified | Not Identified | Strong Buy | Hold |
2/1/2024 | Goldman Sachs | Paul K Choi | Not Available | Strong Buy |
11/17/2023 | Guggenheim Securities | Michael Schmidt | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.22 |
ABR (Last week) | 1.22 |
# of Recs in ABR | 18 |
Average Target Price | $61.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.88 |